日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.

TROP2/claudin 程序介导免疫排斥,从而阻碍乳腺癌中的检查点阻断。

Wu Bogang, Thant Win, Bitman Elena, Liu Ting, Liu Jie, Paschalis Eleftherios I, Patel Bidish K, Nawrocki Cole, Xu Katherine H, Nieman Linda T, Ting David T, de Gois Macedo Bruna, Cheng Yang, Jiang Kevin, Sun Fengfei, Thimmiah Nayana, Sun Sheng, Abelman Rachel O, Bossuyt Veerle I, Isakoff Steven J, Spring Laura M, Bardia Aditya, Ellisen Leif W

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer

ESR1突变转移性乳腺癌中与依拉司特疗效相关的临床和基因组因素

Lloyd, Maxwell R; Weipert, Caroline M; Ali, Azka; Solomon, Sheila R; Saha, Jayati; Lipsyc-Sharf, Marla D; Hamilton, Erika P; Kalinsky, Kevin; Brufsky, Adam M; Bardia, Aditya; Zhang, Nicole; Wander, Seth A

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis

早期乳腺癌患者接受曲妥珠单抗联合或不联合蒽环类药物治疗后,长期心力衰竭风险的社会经济差异:基于SEER-Medicare数据库的分析

Britten, Karissa; Lipsyc-Sharf, Marla; Yang, Eric H; McCloskey, Susan; Sedrak, Mina S; Teshome, Mediget; LaBarbera, Julia; Bardia, Aditya; McAndrew, Nicholas

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial

帕博利珠单抗联合化疗治疗高危早期ER(+)/HER2(-)乳腺癌:一项随机3期试验

Cardoso, Fatima; O'Shaughnessy, Joyce; Liu, Zhenzhen; McArthur, Heather; Schmid, Peter; Cortes, Javier; Harbeck, Nadia; Telli, Melinda L; Cescon, David W; Fasching, Peter A; Shao, Zhimin; Loirat, Delphine; Park, Yeon Hee; Fernandez, Manuel Gonzalez; Rubovszky, Gábor; Spring, Laura; Im, Seock-Ah; Hui, Rina; Takano, Toshimi; André, Fabrice; Yasojima, Hiroyuki; Ding, Yu; Jia, Liyi; Karantza, Vassiliki; Tryfonidis, Konstantinos; Bardia, Aditya

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01

达托泊单抗德鲁替康对比化疗治疗既往接受过治疗的不可手术/转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌:TROPION-Breast01研究的主要结果

Bardia, Aditya; Jhaveri, Komal; Im, Seock-Ah; Pernas, Sonia; De Laurentiis, Michelino; Wang, Shusen; Martínez Jañez, Noelia; Borges, Giuliano; Cescon, David W; Hattori, Masaya; Lu, Yen-Shen; Hamilton, Erika; Zhang, Qingyuan; Tsurutani, Junji; Kalinsky, Kevin; Rubini Liedke, Pedro Emanuel; Xu, Lu; Fairhurst, Rick M; Khan, Sabrina; Denduluri, Neelima; Rugo, Hope S; Xu, Binghe; Pistilli, Barbara

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

瑞博西尼联合内分泌治疗激素受体阳性/ERBB2阴性早期乳腺癌:NATALEE随机临床试验的4年结果

Fasching, Peter A; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Xu, Binghe; Loi, Sherene; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Hortobagyi, Gabriel N; Slamon, Dennis J; Fresco, Rodrigo; Zarate, Juan Pablo; Li, Zheng; Waters, Sorcha; Hurvitz, Sara A

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.

从临床到实验室的转化分析:激素受体阳性转移性乳腺癌中 NF1 改变和 CDK4/6 抑制剂耐药性

Lloyd Maxwell R, Chica-Parrado Rosario, Weipert Caroline M, Knepper Todd C, Podany Emily L, Napolitano Fabiana, Ye Dan, Lin Chang-Ching, Uemoto Yasuaki, Liao Jiemin, Wegrzyn Claire, Walko Christine M, Ryan Lianne Y, Keenan Jennifer C, Medford Arielle J, Liu Shiyuan A, Wulf Gerburg M, Clifton Katherine K, Ma Cynthia X, Han Hyo S, Zhang Nicole, Ellisen Leif W, Bardia Aditya, Arteaga Carlos L, Hanker Ariella B, Wander Seth A

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

转移性乳腺癌患者中TOP1突变和抗体药物偶联物的交叉耐药性

Abelman Rachel O, Wu Bogang, Barnes Haley, Medford Arielle, Norden Bryanna, Putur Annika, Bitman Elena, Thant Win, Liu Ting, Weipert Caroline, Fell Geoffrey, Spring Laura M, Wander Seth A, Moy Beverly, Vidula Neelima, Isakoff Steven J, Varkaris Andreas, Juric Dejan, Corcoran Ryan B, Ellisen Leif W, Bardia Aditya

Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer

转移性乳腺癌中ctDNA谱、靶向治疗使用和预后的种族差异

Podany, Emily L; Foffano, Lorenzo; Gerratana, Lorenzo; Medford, Arielle J; Clifton, Katherine; Tapiavala, Shaili; Velimirovic, Marko; Lipsyc-Sharf, Marla; Reduzzi, Carolina; Bubie, Adrian; Putur, Annika; Ademuyiwa, Foluso O; Puglisi, Fabio; Gradishar, William J; Ma, Cynthia X; Bardia, Aditya; Cristofanilli, Massimo; Davis, Andrew A

CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors.

CDKN1B (p27/kip1) 通过限制有丝分裂抑制剂后的多倍体化来增强耐药持久性 CTC

Horwitz Elad, Dubash Taronish D, Szabolcs Annamaria, Wittner Ben S, Kreuzer Johannes, Morris Robert, Bardia Aditya, Chirn Brian, Wiley Devon, Che Dante, Russell Hunter C, Herrera Lopez Xcanda Ixchel, Fox Douglas B, Antmen Ezgi, Burr Risa, Ting David T, Haas Wilhelm, Sade-Feldman Moshe, Maheswaran Shyamala, Haber Daniel A